Security record
VRNA
Verona Pharma plc · Healthcare · Biotechnology
17Tracked holders
-1Δ holders
15.38MShares held
$1.64BReported value
+3New positions
−4Exits
Momentum inputs (comparable managers):
holder breadth -5.6% ·
share flow -4.7% ·
net new positions -5.9%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
Ownership over time
Who holds it · Q3 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 3.83M | +1013.4% | $408.35M | 0.0% | ▲ Add | 2 | SEC ↗ ×7 |
| 2 | JPMorgan Chase ✦ | 2.83M | — | $301.94M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 3 | Goldman Sachs Group ✦ | 1.94M | — | $206.51M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Millennium Management ✦ | 1.80M | +376.4% | $191.73M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 5 | Morgan Stanley ✦ | 1.58M | — | $168.16M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 6 | Duquesne Family Office ✦ | 1.00M | 0.0% | $106.93M | 2.7% | Held | 5 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 615.90K | +317.8% | $65.72M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 461.87K | -66.9% | $49.29M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 9 | D. E. Shaw & Co. ✦ | 337.14K | -76.2% | $35.98M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | Soros Fund Management ✦ | 285.19K | New | $30.43M | 0.7% | New | 1 | SEC ↗ |
| 11 | Arrowstreet Capital ✦ | 185.30K | New | $19.77M | 0.0% | New | 1 | SEC ↗ |
| 12 | GAMCO Investors ✦ | 163.80K | New | $17.48M | 0.2% | New | 1 | SEC ↗ |
| 13 | Marshall Wace ✦ | 147.77K | +460.8% | $15.77M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 14 | State Street Global Advisors ✦ (passive) | 74.35K | +1076.4% | $7.93M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | Geode Capital Management ✦ (passive) | 72.14K | +5.4% | $7.70M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 50.00K | -85.7% | $5.34M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 17 | Wellington Management ✦ | 18.63K | -98.9% | $1.99M | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Soros Fund Management | $30.43M | 0.7% |
| Arrowstreet Capital | $19.77M | 0.0% |
| GAMCO Investors | $17.48M | 0.2% |
Exited
| T. Rowe Price | $169.25M | was 0.0% |
| Adage Capital Partners | $77.24M | was 0.1% |
| Fidelity (FMR) | $29.55M | was 0.0% |
| Point72 Asset Management | $11.22M | was 0.0% |
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2025 ·
Methodology ·
Get this via the API